biotech investing Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
biotech investing Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
biotech investing Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
biotech investing Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
biotech investing Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
biotech investing Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
biotech investing Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
biotech investing Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
biotech investing Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
biotech investing Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
biotech investing Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
biotech investing At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
Brixton Metals Announces Closing of Option Agreement to Acquire a 100% Interest in the Silver Focused Silvergruvan Project in Sweden
